(R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl 2-cyclopropyl-2-oxoacetate

ID: ALA5191461

Chembl Id: CHEMBL5191461

PubChem CID: 168287864

Max Phase: Preclinical

Molecular Formula: C21H20O7

Molecular Weight: 384.38

Names and Identifiers

Canonical SMILES:  CC(C)=CC[C@@H](OC(=O)C(=O)C1CC1)C1=CC(=O)c2c(O)ccc(O)c2C1=O

Standard InChI:  InChI=1S/C21H20O7/c1-10(2)3-8-16(28-21(27)19(25)11-4-5-11)12-9-15(24)17-13(22)6-7-14(23)18(17)20(12)26/h3,6-7,9,11,16,22-23H,4-5,8H2,1-2H3/t16-/m1/s1

Standard InChI Key:  SVEWBJCQHFATCQ-MRXNPFEDSA-N

Alternative Forms

1. Parent:

   

   ALA5191461

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 384.38

Molecular Weight (Monoisotopic): 384.1209

AlogP: 2.65

#Rotatable Bonds: 6

Polar Surface Area: 117.97

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 8.50

CX Basic pKa: ┄

CX LogP: 4.76

CX LogD: 4.72

Aromatic Rings: 1

Heavy Atoms: 28

QED Weighted: 0.33

Np Likeness Score: 1.86

References

1. Valipour M..  (2022)  Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.,  235  [PMID:35367708] [10.1016/j.ejmech.2022.114314]

Source

Source(1):

• Scientific Literature